Evidence map›Paper›PMID 28239648›Full record

ArticleJCI insight2017

Liver X receptor

Bradlee L Heckmann, Xiaodong Zhang, Alicia M Saarinen, Gabriele Schoiswohl, Erin E Kershaw, Rudolf Zechner, Jun Liu

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. A CThe New phytologist · 2026
    Article
  2. Review
  3. Article
  4. Recent advances on the role of G0S2.Discover oncology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Heliyon · 2024
    Review
  9. Review
  10. Article
  11. The effect ofFrontiers in endocrinology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. The clearance of dead cells by efferocytosis.Nature reviews. Molecular cell biology · 2020
    Review
  20. Identification of an intrinsic lysophosphatidic acid acyltransferase activity in the lipolytic inhibitor GFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Bradlee L HeckmannDepartment of Biochemistry and Molecular Biology.
Xiaodong ZhangDepartment of Biochemistry and Molecular Biology.
Alicia M SaarinenDepartment of Biochemistry and Molecular Biology.
Gabriele SchoiswohlDivision of Endocrinology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Erin E KershawDivision of Endocrinology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Rudolf ZechnerInstitute of Molecular Biosciences, University of Graz, Graz, Austria.
Jun LiuDepartment of Biochemistry and Molecular Biology.
University of Pittsburgh · USMayo Clinic · USUniversity of Graz · AT

Funding

Inhibition of ATGL-Mediated Lipolysis by G0S2R01DK089178 · NIDDK · UNIVERSITY OF KENTUCKY · PI LIU, JUN · 2010 to 2014
$1.7M
Adipose Triglyceride Lipase (ATGL) in Lipotoxicity and The Metabolic SyndromeR01DK090166 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KERSHAW, ERIN E. · 2011 to 2015
$1.7M
Regulation of Hepatic Lipid Accumulation and Insulin ResistanceR01DK109096 · NIDDK · MAYO CLINIC ROCHESTER · PI LIU, JUN · 2016 to 2019
$1.5M
G0S2: a dual-function regulator of lipid and energy metabolismR56DK089178 · NIDDK · MAYO CLINIC ARIZONA · PI LIU, JUN · 2015 to 2015
$125k
Adipocyte lipolysis, adipose tissue function, and lipodystrophyR56DK090166 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KERSHAW, ERIN E. · 2016 to 2016
$116k
NIDDK NIH HHS R01 DK089178NIDDK NIH HHS R01 DK090166NIDDK NIH HHS R01 DK109096NIDDK NIH HHS R56 DK089178NIDDK NIH HHS R56 DK090166
6 · The paper itself

Abstract

Liver X receptors (LXRs) are transcription factors essential for cholesterol homeostasis and lipogenesis. LXRα has been implicated in regulating hepatic triglyceride (TG) accumulation upon both influx of adipose-derived fatty acids (FAs) during fasting and stimulation of de novo FA synthesis by chemical agonism of LXR. However, whether or not a convergent mechanism is employed to drive deposition of FAs from these 2 different sources in TGs is undetermined. Here, we report that the G0/G1 Switch Gene 2 (G0S2), a selective inhibitor of intracellular TG hydrolysis/lipolysis, is a direct target gene of LXRα. Transcriptional activation is conferred by LXRα binding to a direct repeat 4 (DR4) motif in the G0S2 promoter. While LXRα

Indexed as

AnimalsArabidopsis ProteinsBenzenesulfonamidesCell Cycle ProteinsCholesterol, HDLFastingFatty LiverFluorocarbonsHydrocarbons, FluorinatedHydrolysisHypertriglyceridemiaLipolysisLiverLiver X ReceptorsMiceMice, KnockoutArabidopsis ProteinsBenzenesulfonamidesCell Cycle ProteinsCholesterol, HDLERA1 protein, ArabidopsisFluorocarbonsG0S2 protein, mouseHydrocarbons, FluorinatedLiver X ReceptorsNr1h3 protein, mouseSulfonamidesT0901317Triglycerides

Identifiers

PMID28239648
PMCPMC5313069
OpenAlexW2588914123

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.